News | Cardiovascular Business | September 27, 2023

HeartBeam Announces Senior Management Team Appointments

Cardiac technology company HeartBeam has announced senior management appointments to support its 3D-vector electrocardiogram (VECG) platform technology.

Cardiac technology company HeartBeam has announced senior management appointments to support its 3D-vector electrocardiogram (VECG) platform technology. Image courtesy: HeartBeam


September 27, 2023 — HeartBeam, Inc., a Santa Clara, CA-based cardiac technology company, has appointed Richa Gujarati as Senior Vice President, Product, and Pooja Chatterjee as Vice President, Clinical. Gujarati will have direct responsibility for product roadmap and go-to-market strategy and execution at HeartBeam. Chatterjee will be responsible for strategic and tactical leadership of the clinical pipeline, with the objective of securing FDA clearances to support commercialization. According to a statement announcing the senior management team appointments, the company has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (AI).

Richa Gujarati has over 13 years of experience collecting market-level insights and translating them into business needs, driving overall product portfolio and go-to-market strategy. Prior to joining HeartBeam, Richa was Vice President of Product & Go-To-Market Strategy at NextSense. Previously, she was Head of Health Products, Apple Watch, at Apple, building and launching applications in the wearable sensor space, including exploring new revenue models through payer and pharma partnerships. She was also Senior Manager, Product Management & Marketing at iRhythm Technologies, focused on building and selling the Zio line of digital cardiac monitoring products and associated patient apps and Electronic Health Records integration services.

Pooja Chatterjee brings over 15 years of extensive clinical leadership experience in the medical device industry. Her expertise spans a wide range of clinical responsibilities, including field engineering, clinical portfolio strategy and study execution resulting in multiple FDA approvals. She has hands-on experience with a wide range of medical technologies including heart failure, electrophysiology, cardiac rhythm management, diagnostics, and sleep therapy. Previously she held several positions at Abbott Medical Devices, most recently as Global Clinical Project Director, where she defined and executed clinical goals leading to product approvals, indication expansion and publications in key journals.

“We welcome Richa and Pooja to HeartBeam’s leadership team and look forward to leveraging their extensive experience to help bring our ambulatory VECG products to market,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam. “Richa’s deep expertise in go-to-market strategies for health sensing technologies will be instrumental as we ready the HeartBeam AIMIGo VECG device for limited market release during the second half of 2024,” he noted. “Pooja will play a pivotal role leading the validation of our technologies, including FDA 510(k) clearance for the HeartBeam AIMIGo VECG device and post-market regulatory required studies. Together they will add to our growing team of medical and technology experts as we progress toward our initial clearances and the commercial availability of our technology,” Vajdic added.

The senior management team announced also offered the following details on its 3D-vector ECG platform: By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. The company further reports that its HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms.

HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies.

More information: www.Heartbeam.com


Related Content

News | Cardiovascular Business

June 20, 2024 — Allied health professionals such as radiology technologists and therapists can generate millions of ...

Home June 20, 2024
Home
News | Cardiovascular Business

It is with great sadness that the DAIC/ITN team learned of the sudden passing of former Editor Cristen Bolan on June 17 ...

Home June 19, 2024
Home
News | Cardiovascular Business

June 18, 2024 — Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (DMD), a ...

Home June 18, 2024
Home
News | Cardiovascular Business

June 13, 2024 — Frederick St. Goar, MD, medical director at the Norma Melchor Heart & Vascular Institute, was ...

Home June 13, 2024
Home
News | Cardiovascular Business

June 11, 2024 — Columbia University Irving Medical Center’s CUIMC Division of Cardiology has launched the Mitral and ...

Home June 11, 2024
Home
Feature | Cardiovascular Business

June 7, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of the ...

Home June 07, 2024
Home
News | Cardiovascular Business

June 5, 2024 — Edwards Lifesciences announced it has entered into a definitive agreement to sell its Critical Care ...

Home June 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a look at the Top 10 pieces of content viewers were reading during the month of May. 1. American College of ...

Home June 04, 2024
Home
News | Cardiovascular Business

May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part ...

Home May 31, 2024
Home
News | Cardiovascular Business

May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership ...

Home May 22, 2024
Home
Subscribe Now